marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Qualigen Therapeutics Balance Sheet 2011-2024 | QLGN
Annual Balance Sheet Qualigen Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.49 M | -15.9 M | 2.07 M | -1.7 M | -7.81 M | -22.6 M | -7.05 M | -15.8 M | - | - | - | - |
Long Term Debt |
1.3 M | 1.54 M | 306 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
241 K | 134 K | 255 K | 100 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 308 K | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
8.61 M | 4.64 M | 10.4 M | 1.7 M | 5.93 M | 2.71 M | 3.13 M | 1.35 M | - | - | - | - |
Total Liabilities |
10.3 M | 6.27 M | 5.65 M | 1.7 M | 5.93 M | 2.71 M | 3.13 M | 1.35 M | - | - | - | - |
Deferred Revenue |
- | - | 377 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-103 M | -84.7 M | -47.3 M | -80.3 M | -70.2 M | -53.3 M | -45.5 M | -27.1 M | - | - | - | - |
Total Assets |
19.1 M | 22.8 M | 3.72 M | 2.8 M | 15.3 M | 22.8 M | 7.24 M | 16 M | - | - | - | - |
Cash and Cash Equivalents |
7.03 M | 17.5 M | 24 M | 1.7 M | 7.81 M | 22.6 M | 7.05 M | 15.8 M | 2.75 M | - | - | - |
Book Value |
8.77 M | 16.6 M | -1.93 M | 1.1 M | 9.39 M | 20.1 M | 4.1 M | 14.7 M | - | - | - | - |
Total Shareholders Equity |
7.24 M | 16.6 M | 18.3 M | 1.1 M | 9.39 M | 20.1 M | 4.1 M | 14.7 M | -14.5 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Qualigen Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | 1.17 M | 1.24 M | 1.3 M | 1.37 M | 1.43 M | 1.48 M | 1.54 M | 25 K | 98.1 K | 15.6 K | 139 K | 947 K | 1.33 M | 2.22 M | - | 10.3 K | 40.8 K | 70.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 5.96 M | 9.84 M | 9.71 M | 10.3 M | 7.04 M | 7.88 M | 5.19 M | 6.27 M | 5.56 M | 7.63 M | 9.51 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | - | 2.84 M | 2.88 M | 4.13 M | 5.93 M | - | 5.93 M | 5.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 95.2 K | 95.2 K | 69.6 K | 105 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-122 M | -120 M | -119 M | -117 M | -114 M | -111 M | -107 M | -103 M | -97 M | -93.2 M | -89.1 M | -84.7 M | -78.7 M | -75.8 M | -70.5 M | -66.8 M | -66.8 M | -66.8 M | -66.8 M | -80.3 M | -79.9 M | -77.7 M | -74.9 M | -70.2 M | -70.2 M | -70.2 M | -70.2 M | -53.3 M | -53.3 M | -53.3 M | -53.3 M | -45.5 M | -45.5 M | -45.5 M | -45.5 M | -27.1 M | -27.1 M | -27.1 M | -27.1 M | -17.9 M | -17.9 M | -17.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.31 M | 534 K | 1 M | 2.03 M | 4.32 M | 13.1 M | 15.9 M | 19.1 M | 23 M | 26.3 M | 18.7 M | 22.8 M | 16.4 M | 19.9 M | 25.7 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 2.8 M | 2.9 M | 5.01 M | 8.96 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 7.24 M | 7.24 M | 7.24 M | 7.24 M | 16 M | 16 M | 16 M | 16 M | 2.96 M | 2.96 M | 2.96 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
388 K | 119 K | 93.2 K | 402 K | 2.07 M | 591 K | 1.53 M | 3.17 M | 6.62 M | 9.75 M | 13.6 M | 17.5 M | 12.3 M | 15.2 M | 21.9 M | 24 M | 14.5 M | 24 M | 24 M | 1.7 M | 1.96 M | 71.2 K | 5.52 M | 7.81 M | 7.81 M | 7.81 M | 7.81 M | 22.6 M | 22.6 M | 22.6 M | 22.6 M | 7.05 M | 7.05 M | 7.05 M | 7.05 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 2.75 M | 2.75 M | 2.75 M | - | 448 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | -1.64 M | 3.31 M | 6.2 M | 8.77 M | 15.9 M | 18.5 M | 13.5 M | 16.6 M | 10.8 M | 12.3 M | 16.2 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 2.8 M | 62.9 K | 2.14 M | 4.83 M | 9.39 M | 15.3 M | 9.39 M | 9.39 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 7.24 M | 7.24 M | 7.24 M | 7.24 M | 16 M | 16 M | 16 M | 16 M | 2.96 M | 2.96 M | 2.96 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-2.14 M | -4.28 M | -3.52 M | -2.1 M | -1.64 M | 3.31 M | 6.2 M | 7.24 M | 15.9 M | 18.5 M | 13.5 M | 16.6 M | 10.7 M | 12.3 M | 16.2 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | -1.06 M | -1.1 M | -743 K | 1.1 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 4.14 M | 4.1 M | 4.1 M | 4.1 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | -14.5 M | -14.5 M | -14.5 M | - | -12.8 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency